Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H ( (HK:2591) ) has issued an announcement.
Guangzhou Innogen Pharmaceutical Group has announced that China’s Ministry of Agriculture and Rural Affairs has officially accepted its Investigational New Veterinary Drug application for Efsubaglutide Alfa, a core product being developed for the treatment of diabetes in companion animals, with Phase I clinical trials expected to begin in the first quarter of 2026. The company views diabetic medicines for pets as a high-potential market aligned with its long-term strategy, noting that positive pre-clinical efficacy and safety data support further development and potential registration, which could lay the groundwork for a broader expansion into companion animal drug products, although successful commercialization is not guaranteed.
The most recent analyst rating on (HK:2591) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Guangzhou Innogen Pharmaceutical Group Co Ltd Class H stock, see the HK:2591 Stock Forecast page.
More about Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
Guangzhou Innogen Pharmaceutical Group Co., Ltd. is a China-based pharmaceutical company whose business includes the research and development of innovative drug products, and it is now extending its focus into the companion animal health market, particularly targeting treatments for pet diabetes.
Average Trading Volume: 1,030,530
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$13.17B
For an in-depth examination of 2591 stock, go to TipRanks’ Overview page.